内容摘要：para quien la votación del domingo será ahora determinante a la hora de medir su poder de convocatoria. Si bien los partidos políticos no pueden promover a ningún candidato, desde el gobierno se ha insistido a sus seguidores a participar en la votación.

para quien la votación del domingo será ahora determinante a la hora de medir su poder de convocatoria. Si bien los partidos políticos no pueden promover a ningún candidato, desde el gobierno se ha insistido a sus seguidores a participar en la votación.

and identify patients who maythat can modestly slow the memory-destroying disease.

The test can aid doctors in determining whether a patient’s memory problems are due to Alzheimer’s or a number of other medical conditions that can cause cognitive difficulties. The Food and Drug Administration cleared it for patients 55 and older who are showing early signs of the disease.More than 6 million people in the United States and millions more around the world have Alzheimer’s, the most common form of dementia.The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker for Alzheimer’s. Previously, the only FDA-approved methods for detecting amyloid were invasive tests of spinal fluid or expensive PET scans.

The lower costs and convenience of a blood test could also help expand use of two new drugs, Leqembi and Kisunla, which have been shown to slightly slow the progression of Alzheimer’s by clearing amyloid from the brain. Doctors are required to test patients for the plaque before prescribing the drugs, which require regular IV infusions.“Today’s clearance is an important step for Alzheimer’s disease diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease,” said Dr. Michelle Tarver, of FDA’s center for devices.

A number of specialty hospitals and laboratories have already developed their own in-house tests for amyloid in recent years. But those tests aren’t reviewed by the FDA and generally aren’t covered by insurance. Doctors have also had little data to judge which tests are reliable and accurate, leading to an unregulated marketplace that some have called a “wild west.”

Several larger diagnostic and drug companies are also developing their own tests for FDA approval, including Roche, Eli Lilly and C2N Diagnostics.“Star Trek” actor William Shatner caught a lift to space with Blue Origin in 2021 at age 90, soon after Bezos’ inaugural trip. He was followed by former New York Giants defensive end and TV host Michael Strahan and Laura Shepard Churchley, the eldest daughter of Mercury astronaut Alan Shepard, for whom the rocket is named. Two aviation pioneers who missed out on space when they were younger — Wally Funk and Ed Dwight — also rocketed away at ages 82 and 90, respectively.

Most of Blue Origin’s passengers — 58 counting the latest launch — have been business or science types, TV hosts or YouTubers. Ticket prices are not disclosed.This image taken from video provided by Blue Origin shows the New Shepard rocket blasting off in West Texas, Monday, April 14, 2025. (Blue Origin via AP)

This image taken from video provided by Blue Origin shows the New Shepard rocket blasting off in West Texas, Monday, April 14, 2025. (Blue Origin via AP)The Russian Space Agency also has launched its share of space tourists, beginning with a California financier in 2001. Two decades later, a Russian actress filmed aboard the International Space Station.